IL6R and melanoma: Metastatic melanoma patients treated with chemotherapy or immune checkpoint inhibitors with increased levels of the aforementioned factors characterized shorter overall survival [218]; also, patients with melanoma overexpressing IL-6R had shorter survival [215].